The Development and Use of T Cell Receptor Peptide Vaccines
Autoreactivity is a normal feature of the immune system which must be able to distinguish self from non-self. However, when this autoreactivity results in pathological tissue damage, autoimmune diseases result. While autoimmune diseases can be associated with autoreactive T cells or autoantibodies, many of the major autoimmune diseases are considered to be T cell mediated. These include rheumatoid arthritis, multiple sclerosis, psoriasis and type I diabetes. In developing strategies to treat T cell mediated autoimmune disease conditions, one can consider the autoreactive T cells as pathogens. Thus, one can approach therapies for T cell mediated autoimmune disease by using strategies similar to those used to control other pathogens, such as virus or bacteria. These include strategies involving immunization with attenuated or subunit forms of these pathogens.
KeywordsRheumatoid Arthritis Experimental Autoimmune Encephalomyelitis Cell Receptor Myelin Basic Protein Experimental Allergic Encephalomyelitis
Unable to display preview. Download preview PDF.
- 4.Burns FR, Li X, Shen N, Offner H, Chou YK, Vandenbark AA, Herber-Katz E. Both rat and mouse T cell receptors specific for the encephalitogenic determinants of myelin basic protein use similar Va. or V0 chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 1989; 169:27–39.PubMedCrossRefGoogle Scholar
- 14.Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, Brostoff SW. Unpublished data.Google Scholar
- 15.Abe J, Takeda T, Watanabe Y, Nakao H, Kobayashi N, Leung DYM, Kohsaka T. Evidence for superantigen production by Yersinia pseudotuberculosis. J Imunol 1993; 151:4183–4188.Google Scholar
- 17.Gold D, Wilson D, Smith R. Unpublished data.Google Scholar
- 18.Moreland LW, Heck LW Jr, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O’Connor RD, Morgan EE, Diveley EE, Chieffo NM, Freeman TD, Carlo DJ, Brostoff SW. vp17 T Cell Receptor Peptide Vaccine: Results of a Phase I Dose-Finding Study in Patients with Rheumatoid Arthritis. Ann NY Acad Sci, in press.Google Scholar